Decheng Capital Management Iii (Cayman), LLC Equillium, Inc. Transaction History
Decheng Capital Management Iii (Cayman), LLC
- $181 Million
- Q3 2023
A detailed history of Decheng Capital Management Iii (Cayman), LLC transactions in Equillium, Inc. stock. As of the latest transaction made, Decheng Capital Management Iii (Cayman), LLC holds 4,447,308 shares of EQ stock, worth $6.09 Million. This represents 1.82% of its overall portfolio holdings.
Number of Shares
4,447,308
Previous 4,447,308
-0.0%
Holding current value
$6.09 Million
Previous $3.34 Million
1.32%
% of portfolio
1.82%
Previous 1.77%
Shares
1 transactions
Others Institutions Holding EQ
# of Institutions
27Shares Held
11.5MCall Options Held
38.1KPut Options Held
0-
Decheng Capital LLC Menlo Park, CA4.45MShares$6.09 Million0.94% of portfolio
-
Vanguard Group Inc Valley Forge, PA842KShares$1.15 Million0.0% of portfolio
-
Cota Capital Management, LLC San Francisco, CA562KShares$770,3201.37% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny300KShares$411,5480.0% of portfolio
-
Geode Capital Management, LLC Boston, MA216KShares$296,1990.0% of portfolio
About Equillium, Inc.
- Ticker EQ
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,352,100
- Market Cap $47.1M
- Description
- Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...